Compare DexCom, Inc. (DXCM) vs 3M Company (MMM) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

3M (MMM) trades at $156.62, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows strong profitability with 72.14% ROE and 11.14% net margin, though revenue has declined from $34.2B in 2022 to $24.95B in 2025. Recent earnings beats and positive news around wildfire mask demand and Airbus partnerships provide catalysts, but weak consumer segment and high valuation ratios present challenges.

The outlook remains mixed with analyst consensus at $143 target below current price. While operational improvements and strategic partnerships support growth, investors face risks from consumer weakness, high debt levels, and valuation concerns. The stock offers dividend income but requires careful monitoring of Q2 earnings and consumer spending trends.